QA: PUMA BIOTECHNOLOGY INC. in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001401667_2023_PUMA_BIOTECHNOLOGY_INC.pdf

Logs

info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001401667, PUMA BIOTECHNOLOGY INC.

  xvar xval
0 AssetsCurrent 134,281,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 1,146,000
3 remainder_Assets 86,632,000
4 LiabilitiesCurrent 77,484,000
5 LiabilitiesNoncurrent 110,141,000
6 remainder_Liabilities 12,826,000
7 CostOfGoodsAndServicesSold 55,093,000
8 SellingGeneralAndAdministrativeExpense 89,978,000
9 ResearchAndDevelopmentExpense 52,240,000
10 remainder_Expenses 7,455,000
11 remainder_Revenues 228,031,000
12 remainder_NetIncome 0
13 remainder_ComprehensiveNetIncome 2,000
  yvar yval
0 Assets 222,059,000
1 Liabilities 200,451,000
2 Expenses 204,766,000
3 Revenues 228,031,000
4 StockholdersEquity 21,608,000
5 NetIncome 23,265,000
6 ComprehensiveNetIncome 23,266,000
7 BaseVar 427,654,500
8 EconomicCapitalRatio 0.286

Edgar->Model Mapping

Feature Distribution

Change over Time